Context Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company focused on T cell engaging bispecific antibodies for solid tumors, has announced its participation in multiple upcoming investor conferences in April and May 2025.

The company will participate in four major events:

• Stifel Virtual Targeted Oncology Forum (April 8-9) featuring a presentation on April 8 at 10:00 AM ET
• Jones Healthcare and Technology Innovation Conference in Las Vegas (April 8-9)
• 24th Annual Needham Virtual Healthcare Conference (April 7-10)
• Citizens Life Sciences Conference in New York City (May 7-8) with a presentation on May 8 at 2:30 PM ET

The company will conduct one-on-one meetings during all conferences.

PHILADELPHIA, April 01, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its participation in several upcoming investor conferences:

Upcoming Investor Conferences

• Stifel Virtual Targeted Oncology Forum, April 8-9, 2025
  Presentation: Tuesday, April 8 at 10:00 AM ET
  1x1 Meetings on April 8 – 9^th

• Jones Healthcare and Technology Innovation Conference in Las Vegas, April 8-9, 2025
  1x1 Meetings on April 9^th

• 24th Annual Needham Virtual Healthcare Conference, April 7-10, 2025
  1x1 Meetings on April 8^th

• Citizens Life Sciences Conference in New York City, May 7-8, 2025
  Presentation: Thursday, May 8 at 2:30 PM ET
  1x1 Meetings on May 8^th

For additional information or to request a meeting with Context’s management team during these events, please contact your conference representative or IR@contexttherapeutics.com.

About Context Therapeutics^®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company and its employees to participate in and present at conferences, (ii) the potential benefits, characteristics, and side effect profile of our product candidates, (iii) the likelihood data will support future development. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics
IR@contexttherapeutics.com

FAQ

What investor conferences will Context Therapeutics (CNTX) attend in April-May 2025?

CNTX will attend four conferences: Stifel Virtual Targeted Oncology Forum, Jones Healthcare Conference, Needham Virtual Healthcare Conference in April, and Citizens Life Sciences Conference in May 2025.

When will Context Therapeutics (CNTX) present at the Stifel Virtual Oncology Forum?

Context Therapeutics will present at the Stifel Virtual Targeted Oncology Forum on Tuesday, April 8, 2025, at 10:00 AM ET.

Where is the Citizens Life Sciences Conference for CNTX scheduled?

The Citizens Life Sciences Conference will be held in New York City on May 7-8, 2025, with CNTX presenting on May 8 at 2:30 PM ET.

How can investors schedule meetings with Context Therapeutics management at these conferences?

Investors can schedule meetings by contacting their conference representative or emailing IR@contexttherapeutics.com.

What type of company is Context Therapeutics (CNTX)?

Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors.